Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay
Company Will Explore Use of NeXT Personal® in
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for precision oncology, today announced it will continue its
collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global
science-led biopharmaceutical company, to explore ultra-sensitive
molecular residual disease (MRD) measurement, including clinically
relevant and personalized variant tracking, for clinical research
and drug development.
The two companies are collaborating to evaluate the sensitivity
and specificity potential of whole-genome-informed circulating
tumor DNA (ctDNA) testing, while simultaneously detecting and
quantifying clinically relevant mutations in ctDNA that may be used
in the future to help guide therapy when cancer is detected. One
trial, called CALLA, will investigate the role of ctDNA and HPV
detection in plasma in locally advanced cervical cancer.
"Personalis designed NeXT Personal to provide ultra-high
sensitivity and specificity for MRD detection. Our whole-genome,
tumor-informed approach improves ctDNA measurement even when the
plasma tumor fraction is exceptionally low, which is the case in
multiple cancers with low mutational burden. We are pleased that
AstraZeneca is prioritizing such sensitivity, with the aim of
enabling earlier and more personalized interventions for patients,"
said Christopher Hall, President and CEO of Personalis.
As part of the collaboration, Personalis’ NeXT Personal assay
for liquid biopsy will aim to provide ultra-sensitive measurement
of MRD, on-treatment therapy resistance tracking, and better
differentiation between responders and non-responders, as well as
investigate the underlying mechanisms driving cancer.
At Personalis, we are transforming the active management of
cancer through breakthrough personalized testing. We aim to drive a
new paradigm for cancer management, guiding care from biopsy
through the life of the patient. Our highly sensitive assays
combine tumor-and-normal profiling with proprietary algorithms to
deliver advanced insights even as cancer evolves over time. Our
products are designed to detect minimal residual disease (MRD) and
recurrence at the earliest timepoints, enable selection of targeted
therapies based on ultra-comprehensive genomic profiling, and
enhance biomarker strategy for drug development. Personalis is
based in Fremont, California. To learn more, visit
www.personalis.com and connect with us on LinkedIn and Twitter.
Personalis Forward-Looking Statements
All statements in this press release that are not historical are
“forward-looking statements” within the meaning of U.S. securities
laws, including statements relating to attributes or advantages of
NeXT Personal or the NeXT Platform, expected benefits of the
company’s collaboration with AstraZeneca, Personalis’ business
opportunities, leadership, plans or expectations, or other future
events. Such forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from any anticipated results or expectations expressed or implied
by such statements. Factors that could materially affect actual
results can be found in Personalis’ filings with the U.S.
Securities and Exchange Commission, including Personalis’ most
recent reports on Forms 8-K, 10-K and 10-Q, and include those
listed under the caption “Risk Factors.” Personalis disclaims any
obligation to update such forward-looking statements.
version on businesswire.com: https://www.businesswire.com/news/home/20230307005256/en/
Investors: Caroline Corner email@example.com
415-202-5678 Media: Jennifer Temple firstname.lastname@example.org
Historical Stock Chart
From Oct 2023 to Nov 2023
Historical Stock Chart
From Nov 2022 to Nov 2023